BlackRock, Inc. filed Amendment No. 4 to Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 5,450,286 shares of Kymera Therapeutics, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 5,450,286 shares of Kymera Therapeutics common stock.
  • Percent of class: The reported position represents 6.6% of Kymera Therapeutics' outstanding common shares.
  • Sole voting power: BlackRock disclosed sole voting power over 5,331,553 shares.
  • Sole dispositive power: BlackRock disclosed sole dispositive power over 5,450,286 shares.
  • No shared voting or dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Event date: The date of the event requiring the filing is September 30, 2026.
  • Filer classification: BlackRock is identified as a parent holding company (type "HC"), incorporated in Delaware.

BlackRock's Amended 13G Position in Kymera Therapeutics as of September 30, 2026

According to the filing, BlackRock, Inc., headquartered at 50 Hudson Yards, New York, NY 10001, submitted Amendment No. 4 to its Schedule 13G disclosing its beneficial ownership of common stock in Kymera Therapeutics, Inc. (issuer address: 500 North Beacon Street, 4th Floor, Watertown, MA 02472; CUSIP: 501575104). The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026.

The filing discloses that BlackRock beneficially owns 5,450,286 shares, representing 6.6% of the class. Of those shares, BlackRock holds sole voting power over 5,331,553 and sole dispositive power over the full 5,450,286. The filing reports zero shares subject to shared voting or shared dispositive power. The filing notes that the schedule "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it does not include securities beneficially owned by other business units whose beneficial ownership is disaggregated from that of the Reporting Business Units.

Regarding ownership on behalf of other persons, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Kymera Therapeutics, Inc." and that "no one person's interest in the common stock of Kymera Therapeutics, Inc. is more than five percent of the total outstanding common shares." The filing also certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Subsidiary identification is addressed in the filing's Exhibit 99.

What Was Disclosed

BlackRock, Inc. filed Amendment No. 4 to Schedule 13G reporting beneficial ownership of 5,450,286 shares, or 6.6%, of Kymera Therapeutics, Inc. common stock as of September 30, 2026, with sole voting power over 5,331,553 shares and sole dispositive power over all 5,450,286 shares.